Established risk assessment models based on biomarkers generally involves detecting AD-related biomarkers (such as tau protein and Aβ protein in cerebrospinal fluid) and combining them with individual age, gender, family history, and other factors for comprehensive evaluation. This evidence concerns the gene MAPT and Alzheimer disease.